Damage was done earlier when FDA asked, now again on DOJ
The damage was already done earlier on the FDA demand for information. It is interesting that it is happening again, for the same situation, on the DOJ subpoena. Again it will rebound back over $70 but languish for a bit until sales figures come in higher. In the end, it will be much ado about nothing. No penalties, no admission of anything wrong, and it will all just go away.
It will drain focus for a while away from patients who need help, but that is the Hallmark of the Obama administration. "No American Left Unscathed".
See dummy the new agency involved that was brought in is because there is additional evidence that AEGR may not have played by the rules. Try and gloss it over to trick new investors to get into this black widow spider trap. See you on the other side of your midnight. t